• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?转移性肾癌一线靶向抗血管内皮生长因子治疗后的完全缓解：接下来该怎么办？
Ann Transl Med. 2016 Aug;4(15):291. doi: 10.21037/atm.2016.06.25.
2
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.抗血管内皮生长因子受体酪氨酸激酶抑制剂治疗进展后转移性透明细胞肾细胞癌二线靶向治疗的预后因素
Acta Oncol. 2016;55(3):329-40. doi: 10.3109/0284186X.2015.1099731. Epub 2015 Oct 23.
3
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.血管内皮生长因子靶向治疗转移性肾细胞癌患者相关毒性治疗中止的风险因素和预测模型：来自国际转移性肾细胞癌数据库联盟的结果。
Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.
4
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.转移性肾细胞癌患者长期接受血管内皮生长因子靶向治疗的疗效
Clin Genitourin Cancer. 2017 Dec;15(6):e1047-e1053. doi: 10.1016/j.clgc.2017.06.006. Epub 2017 Jun 29.
5
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.转移性肾细胞癌患者在靶向治疗中达到完全缓解的结果：基于登记的分析。
Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30.
6
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.转移性透明细胞肾细胞癌患者中PD-L1表达与血管内皮生长因子靶向治疗临床结局的相关性
Oncologist. 2015 Nov;20(11):1253-60. doi: 10.1634/theoncologist.2015-0151. Epub 2015 Sep 30.
7
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.初始血管内皮生长因子靶向治疗失败的转移性肾细胞癌患者的临床结局。
Urology. 2010 Aug;76(2):430-4. doi: 10.1016/j.urology.2009.12.031. Epub 2010 Mar 12.
8
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.一线使用帕唑帕尼治疗，随后使用血管内皮生长因子受体酪氨酸激酶抑制剂或雷帕霉素靶蛋白抑制剂治疗的未经选择的转移性透明细胞肾细胞癌患者的结局：单机构经验
BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.
9
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.在接受纳武单抗治疗转移性肾细胞癌后获得持久完全缓解的患者中观察到白癜风不良事件。
Front Oncol. 2019 Oct 9;9:1033. doi: 10.3389/fonc.2019.01033. eCollection 2019.
10
Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.一线血管内皮生长因子受体酪氨酸激酶抑制剂及二线治疗耐药的转移性肾细胞癌的三线分子靶向治疗的疗效和安全性。
Int J Clin Oncol. 2018 Jun;23(3):559-567. doi: 10.1007/s10147-018-1241-3. Epub 2018 Jan 11.

引用本文的文献

1
Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.解读线粒体自噬相关特征在透明细胞肾细胞癌临床结局和微环境异质性中的意义。
J Cancer Res Clin Oncol. 2023 Nov;149(17):16015-16030. doi: 10.1007/s00432-023-05349-y. Epub 2023 Sep 9.

本文引用的文献

1
Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.平衡治疗疗效、毒性和并发症风险，治疗老年转移性肾细胞癌患者。
Cancer Treat Rev. 2016 May;46:63-72. doi: 10.1016/j.ctrv.2016.04.002. Epub 2016 Apr 16.
2
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.超越循证数据：驱动转移性肾细胞癌序贯及个性化治疗策略的科学原理与肿瘤行为
Oncotarget. 2016 Apr 19;7(16):21259-71. doi: 10.18632/oncotarget.7267.
3
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.索拉非尼在转移性肾细胞癌中仍有作用吗？索拉非尼与其他靶向药物疗效对比的系统评价和荟萃分析
Crit Rev Oncol Hematol. 2016 Mar;99:324-31. doi: 10.1016/j.critrevonc.2016.01.014. Epub 2016 Jan 19.
4
Sequence of treatment in locally advanced and metastatic renal cell carcinoma.局部晚期和转移性肾细胞癌的治疗顺序
Transl Androl Urol. 2015 Jun;4(3):310-25. doi: 10.3978/j.issn.2223-4683.2015.04.07.
5
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.转移性肾细胞癌患者在靶向治疗中达到完全缓解的结果：基于登记的分析。
Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30.
6
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
7
Renal cancer.肾癌。
Lancet. 2016 Feb 27;387(10021):894-906. doi: 10.1016/S0140-6736(15)00046-X. Epub 2015 Aug 25.
8
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.系统回顾转移性肾细胞癌的测序和系统治疗联合方案。
Eur Urol. 2015 Jan;67(1):100-110. doi: 10.1016/j.eururo.2014.04.006. Epub 2014 May 1.
9
High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.大剂量白细胞介素-2 治疗转移性肾细胞癌：当代经验。
Urology. 2014 May;83(5):1129-34. doi: 10.1016/j.urology.2014.02.005.
10
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.转移性肾细胞癌一线治疗中的靶向治疗和完全缓解。已发表试验的荟萃分析。
Cancer Treat Rev. 2014 Mar;40(2):271-5. doi: 10.1016/j.ctrv.2013.09.003. Epub 2013 Sep 11.

Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

作者信息

Zaffuto Emanuele, Karakiewicz Pierre I, Capitanio Umberto

机构信息

Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; ; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.

出版信息

Ann Transl Med. 2016 Aug;4(15):291. doi: 10.21037/atm.2016.06.25.

DOI:10.21037/atm.2016.06.25
PMID:27568482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4980377/
Abstract
摘要